1
Cook Brian Nicholas, Harcken Christian, Lee Thomas Wai Ho, Liu Pingrong, Mao Can, Lord John, Mao Wang, Raudenbush Brian Christopher, Razavi Hossein, Sarko Christopher Ronald, Swinamer Alan David: Pyrazole compounds as ccr1 antagonists. Boehringer Ingelheim International, Boehringer Ingelheim Pharma & Co Kg, Cook Brian Nicholas, Harcken Christian, Lee Thomas Wai Ho, Liu Pingrong, Mao Can, Lord John, Mao Wang, Raudenbush Brian Christopher, Razavi Hossein, Sarko Christopher Ronald, Swinamer Alan David, MORRIS Michael P, November 12, 2009: WO/2009/137338 (13 worldwide citation)

Disclosed are compounds of the formula I which block the interaction of CCR1 and its ligands and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple scler ...


2

3

4
Bentzien Joerg Martin, Cook Brian Nicholas, Takahashi Hidenori: 2-(ih-thieno [3,2-c] pyrazol-3yl)-ih-indole derivatives and related compounds as tec kinase inhibitors for the treatment of inflammations and immunological disorders. Boehringer Ingelheim International, Boehringer Ingelheim Pharma & Co Kg, Bentzien Joerg Martin, Cook Brian Nicholas, Takahashi Hidenori, MORRIS Michael P, July 5, 2007: WO/2007/076228 (2 worldwide citation)

Disclosed are compounds of formula (I): (F) wherein Ri, R2, X and Ar are defined herein. The compounds of the invention inhibit Itk kinase and are therefore useful for treating diseases and pathological conditions involving inflammation, immunological disorders and allergic disorders. Also disclosed ...


5

6
COOK BRIAN NICHOLAS: Azaindazole compounds as ccr1 receptor antagonists. BOEHRINGER INGELHEIM INTERNATIONAL, Morris Michael P, April 1, 2010: WO/2010/036632 (1 worldwide citation)

Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are methods of making and methods of usin ...


7
BETAGERI Rajashekhar, COOK Brian Nicholas, DISALVO Darren, HARCKEN Christian, KUZMICH Daniel, LIU Pingrong, LORD John, MAO Can, RAZAVI Hossein: COMPOSÉS DE PYRAZOLOPIPÉRIDINE EN TANT QUANTAGONISTES DE RÉCEPTEUR CCR1, PYRAZOLOPIPERIDINE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS. BOEHRINGER INGELHEIM INTERNATIONAL, BETAGERI Rajashekhar, COOK Brian Nicholas, DISALVO Darren, HARCKEN Christian, KUZMICH Daniel, LIU Pingrong, LORD John, MAO Can, RAZAVI Hossein, MORRIS Michael P, June 28, 2012: WO/2012/087782 (1 worldwide citation)

Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are methods of making and methods of usin ...


8

9
Bentzien Joerg Martin, Cook Brian Nicholas, Takahashi Hidenori: 2-(ih-thieno [3,2-c] pyrazol-3yl)-ih-indole derivatives and related compounds as tec kinase inhibitors for the treatment of inflammations and immunological disorders. Boehringer Ingelheim Int, Boehringer Ingelheim Pharma, September 17, 2008: EP1968580-A2

Disclosed are compounds of formula (I): (F) wherein Ri, R2, X and Ar are defined herein. The compounds of the invention inhibit Itk kinase and are therefore useful for treating diseases and pathological conditions involving inflammation, immunological disorders and allergic disorders. Also disclosed ...


10
COOK BRIAN NICHOLAS: Indazole and pyrazolopyridine compounds as ccr1 receptor antagonists. BOEHRINGER INGELHEIM INTERNATIONAL, Morris Michael P, April 28, 2011: WO/2011/049917

Diclosed are CCRl receptor antagonists of the formula (I), wherein X is nitrogen or, C-R2; Ar1 is carbocycle, heteroaryl or heterocyclyl each optionally substituted by one to three Ra; Ar2 is carbocycle, heteroaryl or heterocyclyl, each optionally substituted by one to three Rb; Cyclic G is carbocyc ...